[HTML][HTML] Potential for therapeutic use of hydrogen sulfide in oxidative stress-induced neurodegenerative diseases
R Tabassum, NY Jeong - International Journal of Medical Sciences, 2019 - ncbi.nlm.nih.gov
Oxidative phosphorylation is a source of energy production by which many cells satisfy their
energy requirements. Endogenous reactive oxygen species (ROS) are by-products of …
energy requirements. Endogenous reactive oxygen species (ROS) are by-products of …
The dopamine transporter gene SLC6A3: multidisease risks
MEA Reith, S Kortagere, CE Wiers, H Sun… - Molecular …, 2022 - nature.com
The human dopamine transporter gene SLC6A3 has been consistently implicated in several
neuropsychiatric diseases but the disease mechanism remains elusive. In this risk synthesis …
neuropsychiatric diseases but the disease mechanism remains elusive. In this risk synthesis …
Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view
PA Salles, IF Mata, HH Fernandez - Parkinsonism & Related Disorders, 2021 - Elsevier
Parkinson disease (PD) is a complex heterogeneous neurodegenerative disorder.
Association studies have revealed numerous genetic risk loci and variants, and about 5 …
Association studies have revealed numerous genetic risk loci and variants, and about 5 …
Predictors of motor complications in early Parkinson's disease: A prospective cohort study
MJ Kelly, MA Lawton, F Baig, C Ruffmann… - Movement …, 2019 - Wiley Online Library
Objective The objective of this study was to identify clinical predictors of motor complications
(dyskinesia and motor fluctuations) of levodopa in a prospectively recruited PD cohort using …
(dyskinesia and motor fluctuations) of levodopa in a prospectively recruited PD cohort using …
DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease
C Purcaro, N Vanacore, F Moret, ME Di Battista… - Neuroscience …, 2019 - Elsevier
L-dopa–induced dyskinesias (LID) is a common motor side effect of levodopa therapy of
Parkinson's disease (PD). The identified predictors may only partially account for the risk of …
Parkinson's disease (PD). The identified predictors may only partially account for the risk of …
Modified glutamatergic postsynapse in neurodegenerative disorders
The postsynaptic density (PSD) is a complex subcellular domain important for postsynaptic
signaling, function, and plasticity. The PSD is present at excitatory synapses and specialized …
signaling, function, and plasticity. The PSD is present at excitatory synapses and specialized …
Systems approach to identify common genes and pathways associated with response to selective serotonin reuptake inhibitors and major depression risk
Despite numerous studies on major depressive disorder (MDD) susceptibility, the precise
underlying molecular mechanism has not been elucidated which restricts the development …
underlying molecular mechanism has not been elucidated which restricts the development …
[HTML][HTML] Impact of Parkinson's disease on the efficiency of masticatory cycles: Electromyographic analysis
Impact of Parkinson’s disease on the efficiency of masticatory cycles: Electromyographic
analysis - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
analysis - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
The levodopa response varies in pathologically confirmed Parkinson's disease: a systematic review
V Pitz, N Malek, ES Tobias, KA Grosset… - Movement Disorders …, 2020 - Wiley Online Library
Background A good response to levodopa is a key feature of Parkinson's disease (PD), and
a poor response suggests an alternative diagnosis, but the extent of variation in the …
a poor response suggests an alternative diagnosis, but the extent of variation in the …
Multivariate genomic and transcriptomic determinants of imaging-derived personalized therapeutic needs in Parkinson's disease
C Lenglos, SJ Lin, Y Zeighami, TR Baumeister… - Scientific Reports, 2022 - nature.com
Due to the marked interpersonal neuropathologic and clinical heterogeneity of Parkinson's
disease (PD), current interventions are not personalized and fail to benefit all patients …
disease (PD), current interventions are not personalized and fail to benefit all patients …